Aura Biosciences, Inc. Common Stock (AURA) Stock
NASDAQ · AURA
6.44
Fundamentals
Market cap
$667.86M
Price / Earnings ratio
-5.2x
Price / Sales ratio
N/A
Price / Book ratio
2.2x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Aura Biosciences, Inc. Common Stock
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
SectorHealthcare
IndustryBiotechnology
Employees113
CEOMs. Natalie C. Holles
IPO DateOct 28, 2021
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. J. Jill Hopkins M.D. | Chief Medical Officer & President of Research and Development | 1965 |
| Ms. Natalie C. Holles | President, CEO & Director | 1973 |
| Ms. Amy Elazzouzi | Senior Vice President of Finance, Treasurer and Secretary | 1974 |
| Ms. Susan Abu-Absi Ph.D. | Chief Operating Officer | — |
| Alex Dasalla | Head of Investor Relations & Corporate Communications | — |
| Ms. Julie Person | Chief People Officer | 1974 |
| Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations | — |
| Dr. Anthony Daniels M.D. | VP & Therapeutic Area of Head Ocular Oncology | — |
| Ms. Erica Kratz Ph.D. | Chief Regulatory & Quality Officer | — |
Fundamentals
Valuation
Market cap$667.86M
Price-to-sales ratioN/A
Price-to-book value2.17
Price-earnings ratio-5.20
Return on Equity-78.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.75
Income Statement
Average volume696,797
EBITDA$-109.59M
1 year high (52w)$9.54
1 year low (52w)$4.73
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



